- Home
- NMIH vs MLTX Comparison
NMIH vs MLTX Comparison
Compare NMIH & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMIH
- MLTX
- Stock Information
- Founded
- NMIH 2011
- MLTX 2021
- Country
- NMIH United States
- MLTX Switzerland
- Employees
- NMIH N/A
- MLTX N/A
- Industry
- NMIH Property-Casualty Insurers
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- NMIH Finance
- MLTX Health Care
- Exchange
- NMIH Nasdaq
- MLTX Nasdaq
- Market Cap
- NMIH 2.8B
- MLTX 2.3B
- IPO Year
- NMIH 2013
- MLTX N/A
- Fundamental
- Price
- NMIH $33.68
- MLTX $38.33
- Analyst Decision
- NMIH Buy
- MLTX Strong Buy
- Analyst Count
- NMIH 7
- MLTX 8
- Target Price
- NMIH $42.14
- MLTX $80.50
- AVG Volume (30 Days)
- NMIH 696.5K
- MLTX 489.2K
- Earning Date
- NMIH 04-29-2025
- MLTX 05-06-2025
- Dividend Yield
- NMIH N/A
- MLTX N/A
- EPS Growth
- NMIH 15.37
- MLTX N/A
- EPS
- NMIH 4.43
- MLTX N/A
- Revenue
- NMIH $650,971,000.00
- MLTX N/A
- Revenue This Year
- NMIH N/A
- MLTX $103.42
- Revenue Next Year
- NMIH $5.25
- MLTX N/A
- P/E Ratio
- NMIH $7.60
- MLTX N/A
- Revenue Growth
- NMIH 12.43
- MLTX N/A
- 52 Week Low
- NMIH $29.05
- MLTX $31.42
- 52 Week High
- NMIH $42.49
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- NMIH 42.74
- MLTX 51.82
- Support Level
- NMIH $33.24
- MLTX $31.90
- Resistance Level
- NMIH $34.95
- MLTX $37.73
- Average True Range (ATR)
- NMIH 1.30
- MLTX 2.99
- MACD
- NMIH -0.11
- MLTX 0.29
- Stochastic Oscillator
- NMIH 34.70
- MLTX 74.53
About NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.